Clinicopathologic and11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum
Open accessThe DOI matches its Crossref record; 71 of the 72 references it cites were found in a registry or an index.
Abstract
Thal amyloid phase, which describes the pattern of progressive amyloid-β plaque deposition in Alzheimer's disease, was incorporated into the latest National Institute of Ageing - Alzheimer's Association neuropathologic assessment guidelines. Amyloid biomarkers (positron emission tomography and cerebrospinal fluid) were included in clinical diagnostic guidelines for Alzheimer's disease dementia published by the National Institute of Ageing - Alzheimer's Association and the International Work group. Our first goal was to evaluate the correspondence of Thal amyloid phase to Braak tangle stage and ante-mortem clinical characteristics in a large autopsy cohort. Second, we examined the relevance of Thal amyloid phase in a prospectively-followed autopsied cohort who underwent ante-mortem (11)C-Pittsburgh compound B imaging; using the large autopsy cohort to broaden our perspective of (11)C-Pittsburgh compound B results. The Mayo Clinic Jacksonville Brain Bank case series (n = 3618) was selected regardless of ante-mortem clinical diagnosis and neuropathologic co-morbidities, and all assigned Thal amyloid phase and Braak tangle stage using thioflavin-S fluorescent microscopy. (11)C-Pittsburgh compound B studies from Mayo Clinic Rochester were available for 35 participants scanned within 2 years of death. Cortical (11)C-Pittsburgh compound B values were calculated as a standard uptake value ratio normalized to cerebellum grey/white matter. In the high likelihood Alzheimer's disease brain bank cohort (n = 1375), cases with lower Thal amyloid phases were older at death, had a lower Braak tangle stage, and were less frequently APOE-ε4 positive. Regression modelling in these Alzheimer's disease cases, showed that Braak tangle stage, but not Thal amyloid phase predicted age at onset, disease duration, and final Mini-Mental State Examination score. In contrast, Thal amyloid phase, but not Braak tangle stage or cerebral amyloid angiopathy predicted (11)C-Pittsburgh compound B standard uptake value ratio. In the 35 cases with ante-mortem amyloid imaging, a transition between Thal amyloid phases 1 to 2 seemed to correspond to (11)C-Pittsburgh compound B standard uptake value ratio of 1.4, which when using our pipeline is the cut-off point for detection of clear amyloid-positivity regardless of clinical diagnosis. Alzheimer's disease cases who were older and were APOE-ε4 negative tended to have lower amyloid phases. Although Thal amyloid phase predicted clinical characteristics of Alzheimer's disease patients, the pre-mortem clinical status was driven by Braak tangle stage. Thal amyloid phase correlated best with (11)C-Pittsburgh compound B values, but not Braak tangle stage or cerebral amyloid angiopathy. The (11)C-Pittsburgh compound B cut-off point value of 1.4 was approximately equivalent to a Thal amyloid phase of 1-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For amyloid imaging, where over a decade of data are available, different ligands, methods of image acquisition, and image processing can result in different thresholds when compared to neuropathologic standards [21,22,196].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent studies suggest that NFT pathology closely correlates with neurodegeneration and cognitive decline [1, 2].”
From Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology (2016) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“supports recent evidence that tau may play an early pathological role in Alzheimer’s disease129–131”
From Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing (2019) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“A typical cut point used for 11C Pittsburgh compound B approximately labels individuals with Thal phase 0–1 normal and individuals with Thal phase 2–5 abnormal [21].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282 · cited 1×
“Ante-mortem clinical history for age at onset of cognitive symptoms, education, and Mini-Mental State Examination (MMSE) score (Folstein et al., 1975) was retrospectively abstracted from clinical reports for the Mayo Clinic Jacksonville series, with investigators blinded to Thal amyloid phase.”
MethodHirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 4×
“CSF) have been included in NIA-AA clinical diagnostic guidelines for Alzheimer’s disease dementia (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
BackgroundMethodInfluentialSelf-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 7×
“A Braak NFT stage of 5IV is consistent with NFTs restricted to limbic regions and not yet involving cortical regions (Braak and Braak, 1991).”
BackgroundMethodInfluentialAmyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 2×
“CSF) have been included in NIA-AA clinical diagnostic guidelines for Alzheimer’s disease dementia (Albert et al., 2011; Jack et al., 2011; McKhann et al., 2011).”
MethodSelf-citationSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 2×
“well as preclinical stages of the disease (Jack et al., 2011; McKhann et al., 2011; Sperling et al., 2011).”
BackgroundMethodSelf-citation
Research works printed but not linked: 1
- 10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x · doi:10.1002/1531-8249(199903)45:3<358::aid-ana12>3.0.co;2-x
Cited by
Items 101–200 of 351
Postmortem T 2 * - Weighted MRI Imaging of Cortical Iron Reflects Severity of Alzheimer’s Disease
Bulk, M., Kenkhuis, B., van der Graaf, L. M., Goeman, J. J., Natté, R., & van der Weerd, L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180317 · Cited by 65
“The staging of tau pathology as proposed by Braak better reflects cognitive impairment and is therefore considered as a more reliable biomarker for disease progression (Murray et al., 2015).”
Koehler, D., Shah, Z. A., & Williams, F. E. (2018) · Neurochemistry International · doi:10.1016/j.neuint.2018.10.022 · Cited by 64
Seo, S. W., Ayakta, N., Grinberg, L. T., Villeneuve, S., Lehmann, M., Reed, B., DeCarli, C., Miller, B. L., Rosen, H. J., Boxer, A. L., et al. (2017) · NeuroImage: Clinical · doi:10.1016/j.nicl.2016.11.008 · Cited by 63
“Considering that Braak neurofibrillary score is correlated with amyloid Aβ burden (Murray et al., 2015), it might be reasonable to expect that PiB SUVR would differentiate ADNC levels as well.”
Ikonomović, M. D., Buckley, C. J., Abrahamson, E. E., Kofler, J., Mathis, C. A., Klunk, W. E., & Farrar, G. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02175-1 · Cited by 63
Knopman, D. S., Lundt, E. S., Therneau, T. M., Albertson, S. M., Gunter, J. L., Senjem, M. L., Schwarz, C. G., Mielke, M. M., Machulda, M. M., Boeve, B. F., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2020.3921 · Cited by 61
Self-citationAssociation of anxiety with subcortical amyloidosis in cognitively normal older adults
Hanseeuw, B. J., Jonas, V., Jackson, J., Betensky, R. A., Rentz, D. M., Johnson, K. A., Sperling, R. A., & Donovan, N. J. (2020) · Molecular Psychiatry · doi:10.1038/s41380-018-0214-2 · Cited by 61
“Using [(18)F]flutemetamol [8] or [(11)C]PiB [9] positron emission tomography (PET) to detect Aβ pla-”
MethodGhirelli, A., Tosakulwong, N., Weigand, S. D., Clark, H. M., Ali, F., Botha, H., Duffy, J. R., Utianski, R. L., Buciuc, M., Murray, M. E., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25893 · Cited by 59
“Global PiB SUVR was abnormal in the majority of patients who had a Thal phase 3 or more, as previously reported.(2) One Thal phase 1 case showed abnormal global PiB, which was likely explained by the high Aβ plaque count in this case.”
BackgroundSelf-citationMurray, M. E., Moloney, C. M., Kouri, N., Syrjanen, J. A., Matchett, B. J., Rothberg, D. M., Tranovich, J. F., Sirmans, T. N. H., Wiste, H. J., Boon, B. D. C., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00578-0 · Cited by 55
Self-citationLiu, C., Yamazaki, Y., Heckman, M. G., Martens, Y. A., Jia, L., Yamazaki, A., Diehl, N. N., Zhao, J., Zhao, N., DeTure, M., et al. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12104 · Cited by 58
Self-citationKoychev, I. G., Hofer, M., & FRIEDMAN, N. C. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.230458 · Cited by 58
Alzheimer's disease neuropathology and its estimation with fluid and imaging biomarkers
Thal, D. R., Poesen, K., Vandenberghe, R. R., & Meyer, S. D. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00819-y · Cited by 57
“These biomarkers include positron emission tomography (PET) methods visualizing Aβ or p-τ in the brain with radiolabeled tracers that bind specifically to Aβ and p-τ aggregates [7–11] as well as measurement of Aβ or p-τ levels in cerebrospinal fluid (CSF) [12, 13] and blood [14, 15].”
Kocagöncü, E., Quinn, A. J., Firouzian, A., Cooper, E., Greve, A., Gunn, R. N., Green, G. G. R., Woolrich, M. W., Henson, R. N., Lovestone, S., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.03.009 · Cited by 57
“First, is the recognition of the effect of Tau and Ab on synaptic dysfunction (Ittner et al., 2010; Murray et al., 2015), early in the cascade of Alzheimer pathogenesis and before atrophy or cell death.”
BackgroundSantos, O. A., Pedraza, O., Lucas, J. A., Duara, R., Greig‐Custo, M. T., Hanna Al‐Shaikh, F. S., Liesinger, A. M., Bieniek, K. F., Hinkle, K. M., Lesser, E. R., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.12.013 · Cited by 56
“Rate of cognitive decline was evaluated using three or more MMSE test dates relative to the date of death, and calculated as points lost per year [24]; this was available for n = 297/1625 (18%).”
Self-citationMitochondrial links between brain aging and Alzheimer’s disease
Wilkins, H., & Swerdlow, R. H. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00261-2 · Cited by 56
“This includes an emerging interest in tau [127], whose fibrillar presence in the form of tangles quantitatively correlates well with cognitive decline [128].”
BackgroundWischik, C. M., Bentham, P., Gauthier, S., Miller, S., Kook, K., & Schelter, B. O. (2022) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2022.63 · Cited by 55
“Tau aggregation is a promising target for diseasemodifying AD therapy as it is a hallmark pathology of AD that correlates with AD clinical severity and progression more strongly than amyloid pathology (11, 12).”
BackgroundStefanovski, L., Meier, J. M., Pai, R. K., Triebkorn, P., Lett, T. A. P., Martin, L., Bülau, K., Hofmann‐Apitius, M., Solodkin, A., McIntosh, A. R., et al. (2021) · Frontiers in Neuroinformatics · doi:10.3389/fninf.2021.630172 · Cited by 55
“…precuneus (Alongi et al., 2019 ); striatum in hereditary PSEN1 patients (Klunk et al., 2007) and PSEN1 / APP patients ( Villemagne et al., 2009); (Murray et al., 2015 ) Middle to high Braak stages in HC, but age-related and associated with ApoE: with 11 C-PIB ( Jack et al., 2014 ), meta-analysis…”
BackgroundA multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer’s disease
Sepulveda-Falla, D., Chavez-Gutierrez, L., Portelius, E., Vélez, J. I., Dujardin, S., Barrera-Ocampo, A., Dinkel, F., Hagel, C., Puig, B., Mastronardi, C., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02249-0 · Cited by 54
“Recent studies in SAD demonstrate that different patterns of tau phosphorylation are associated with both age of onset and rate of clinical progression of disease [15], and that tau pathology is the driver of disease severity instead of Aβ pathology burden [36], suggesting that a similar phenomenon may help to explain…”
BackgroundBergeron‐Brlek, M., Goodwin‐Tindall, J., Cekic, N., Roth, C., Zandberg, W. F., Shan, X., Varghese, V., Chan, S., Davies, G. J., Vocadlo, D. J., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201507985 · Cited by 54
The emerging role of PET imaging in dementia
Iaccarino, L., Sala, A., Caminiti, S. P., & Perani, D. (2017) · F1000Research · doi:10.12688/f1000research.11603.1 · Cited by 50
Nasoohi, S., Parveen, K., & Ishrat, T. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-180735 · Cited by 50
“Although such vulnerability might be partly described based on the inherited apolipoprotein (cid:2) 4 allele (APOE (cid:2) 4) risk gene [8, 9], heredity may not entirely explain familial AD and shared cultural, environmental and lifestyle factors might be arguably involved.”
Comparison of neurotoxicity of different aggregated forms of Aβ40, Aβ42 and Aβ43 in cell cultures
Fu, L., Sun, Y., Guo, Y., Chen, Y., Yu, B., Zhang, H., Wu, J., Yu, X., Kong, W., & Wu, H. (2017) · Journal of Peptide Science · doi:10.1002/psc.2975 · Cited by 52
Calcium-Sensing Receptors of Human Neural Cells Play Crucial Roles in Alzheimer's Disease
Chiarini, A., Armato, U., Liu, D., & Dal Prà, I. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00134 · Cited by 51
“An extended post-mortem survey revealed that AD cognitive decline is linked to both Aβs and p-Taues build-ups (Murray et al., 2015).”
BackgroundAlosco, M. L., White, M., Bell, C. A., Faheem, F., Tripodis, Y., Yhang, E., Baucom, Z., Martin, B. M., Palmisano, J. N., Dams-O’Connor, K., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00697-2 · Cited by 51
Long, J. M., Coble, D. W., Xiong, C., Schindler, S. E., Perrin, R. J., Gordon, B. A., Benzinger, T. L. S., Grant, E., Fagan, A. M., Harari, O., et al. (2022) · Brain · doi:10.1093/brain/awac250 · Cited by 52
Thal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0837-9 · Cited by 49
“The correlation of AD progression with increasing tracer retention in amyloid PET seen in our study is in line with other studies [15, 17, 31, 52, 60].”
ResultAssessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes
Tan, R. H., Kril, J. J., Yang, Y., Tom, N., Hodges, J. R., Villemagne, V. L., Rowe, C. C., Leyton, C. E., Kwok, J. B. J., Ittner, L. M., et al. (2017) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2017.05.005 · Cited by 48
Das, S. R., Xie, L., Wisse, L. E. M., Vergnet, N., Ittyerah, R., Cui, S., Yushkevich, P. A., Wolk, D. A., & Initiative, A. D. N. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.05.009 · Cited by 50
Amadoro, G., Latina, V., Corsetti, V., & Calissano, P. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2019.165584 · Cited by 43
Predicted sequence of cortical tau and amyloid-β deposition in Alzheimer disease spectrum
Cho, H., Lee, H. S., Choi, J. Y., Lee, J. H., Ryu, Y. H., Lee, M. S., & Lyoo, C. H. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.04.007 · Cited by 45
Biomarkers: Our Path Towards a Cure for Alzheimer Disease
Tarawneh, R. M. (2020) · Biomarker Insights · doi:10.1177/1177271920976367 · Cited by 46
Sala, A., Nordberg, A. K., Rodriguez‐Vieitez, E., & Initiative, A. D. N. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-00950-w · Cited by 47
Building an adaptive brain across development: targets for neurorehabilitation must begin in infancy
Edgin, J. O., Clark, C. A. C., Massand, E., & Karmiloff‐Smith, A. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00232 · Cited by 46
High-glucose induces tau hyperphosphorylation through activation of TLR9-P38MAPK pathway
Sun, Y., Xiao, Q., Luo, C., Zhao, Y., Pu, D., Zhao, K., Chen, J., Wang, M., & Liao, Z. (2017) · Experimental Cell Research · doi:10.1016/j.yexcr.2017.07.032 · Cited by 45
Amyloid‐ β PET and CSF in an autopsy‐confirmed cohort
Reimand, J., Boon, B. D. C., Collij, L. E., Teunissen, C. E., Rozemüller, A. J. M., van Berckel, B. N. M., Scheltens, P., Ossenkoppele, R., & Bouwman, F. H. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51195 · Cited by 45
Ni, R., Röjdner, J., Voytenko, L. P., Dyrks, T., Thiele, A., Marutle, A., & Nordberg, A. K. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201344 · Cited by 44
Corsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 42
Josephs, K. A., Tosakulwong, N., Weigand, S. D., Graff‐Radford, J., Schwarz, C. G., Senjem, M. L., Machulda, M. M., Kantarci, K., Knopman, D. S., Nguyen, A. T., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado8076 · Cited by 42
Self-citationWhitwell, J. L., Ahlskog, J. E., Tosakulwong, N., Senjem, M. L., Spychalla, A. J., Petersen, R. C., Jack, C. R., Lowe, V. J., & Josephs, K. A. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2017.12.016 · Cited by 38
“Positron emission tomography (PET) ligands that bind to beta-amyloid, such as Pittsburgh Compound B (PiB) [5], have been available for a number of years and show excellent concordance with betaamyloid deposition at autopsy[6].”
BackgroundSelf-citationEpilepsy in Neurodegenerative Dementias: A Clinical, Epidemiological, and EEG Study
Arnaldi, D., Donniaquio, A., Mattioli, P., Massa, F., Grazzini, M., Meli, R., Filippi, L., Grisanti, S. G., Famà, F., Terzaghi, M., et al. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191315 · Cited by 41
Witnessed apneas are associated with elevated tau-PET levels in cognitively unimpaired elderly
Carvalho, D. Z., Louis, E. K. S., Schwarz, C. G., Lowe, V. J., Boeve, B. F., Przybelski, S. A., Reddy, A., Mielke, M. M., Knopman, D. S., Petersen, R. C., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009315 · Cited by 41
“This cutoff selects participants in whom amyloid accumulation is more like likely to occur,(48,49) corresponding to Thal amyloid phases of at least 1 to 2.(50)”
BackgroundSelf-citationKasanuki, K., Ferman, T. J., Murray, M. E., Heckman, M. G., Pedraza, O., Al‐Shaikh, F. S. H., Mishima, T., Diehl, N. N., van Gerpen, J. A., Uitti, R. J., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.02.003 · Cited by 39
Self-citationPET Agents in Dementia: An Overview
van Waarde, A., Marcolini, S., Deyn, P. P. D., & Dierckx, R. (2021) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.008 · Cited by 39
Zeydan, B., Deelchand, D. K., Tosakulwong, N., Lesnick, T. G., Kantarci, O. H., Machulda, M. M., Knopman, D. S., Lowe, V. J., Jack, C. R., Petersen, R. C., et al. (2017) · Journal of Neuroimaging · doi:10.1111/jon.12454 · Cited by 39
Self-citationLi, Q., Wu, X., Xu, L., Chen, K., Yao, L., & Initiative, A. D. N. (2018) · Frontiers in Computational Neuroscience · doi:10.3389/fncom.2017.00117 · Cited by 39
“For classification of AD and CU, the Hippocampus, Inferior Temporal, and ParaHippocampal may be the discriminating biomarkers on sMRI; the Angular, Posterior Cingulum, and Inferior Parietal may be the important regions on FDG-PET; and the Hippocampus and ParaHippocampal may be the key regions on florbetapir-PET.”
BackgroundInfluentialJain, S. K., Stevens, C. M., Margret, J. J., & Levine, S. N. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0245 · Cited by 38
Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation
Novak, P., Cehlar, O., Skrabana, R., & Novak, M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179942 · Cited by 37
“Important questions, such as why massive amyloidosis without tau pathology is asymptomatic, still remain unanswered [4].”
Alzheimer’s Disease Progressively Reduces Visual Functional Network Connectivity
Huang, J., Beach, P. A., Bozoki, A., & Zhu, D. C. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210017 · Cited by 37
Yang, C., Li, X., Gao, W., Wang, Q., Zhang, L., Li, Y., Li, L., & Zhang, L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00682 · Cited by 36
“Data strongly suggest that neurofibrillary pathology contributes to neuronal dysfunction and correlates with the clinical progression of AD (Holtzman et al., 2011; Murray et al., 2015).”
BackgroundEvidence-based Interpretation of Amyloid-β PET Results: A Clinician’s Tool
Bergeron, D., Ossenkoppele, R., & Jr Laforce, R. (2018) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000239 · Cited by 34
Kunkle, B., Grenier-Boley, B., Sims, R., Bis, J., Naj, A., Boland, A., Vronskaya, M., van der Lee, S., Amlie-Wolf, A., Bellenguez, C., et al. (2018) · doi:10.1101/294629 · Cited by 35
Self-citationTuzzi, E., Balla, D. Z., Loureiro, J. R., Neumann, M., Laske, C., Pohmann, R., Preische, O., Scheffler, K., & Hagberg, G. E. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190424 · Cited by 35
Maphis, N. M., Jiang, S., Binder, J., Wright, C., Gopalan, B., Lamb, B. T., & Bhaskar, K. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00069 · Cited by 35
“A growing number of studies implicate reasonably significant positive correlations between the build-up of NFTs and cognitive impairment in various tau-targeted imaging studies in humans (Nelson et al., 2012; Murray et al., 2015; Brier et al., 2016; Ossenkoppele et al., 2016; Scholl et al., 2016).”
BackgroundAge and neurodegeneration imaging biomarkers in persons with Alzheimer disease dementia
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002979 · Cited by 34
Self-citationMicroglia in frontotemporal lobar degeneration with progranulin or C9ORF72 mutations
Sakae, N., Roemer, S. F., Bieniek, K. F., Murray, M. E., Baker, M., Kasanuki, K., Graff‐Radford, N. R., Petrucelli, L., van Blitterswijk, M., Rademakers, R., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50875 · Cited by 34
Self-citationon behalf of the Cognitive Function and Ageing Neuropathology Study Group, Wharton, S. B., Wang, D. Y. Q., Parikh, C. R., Matthews, F. E., Brayne, C., & Ince, P. G. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0858-4 · Cited by 34
Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease
Shirvan, J. C., Clement, N. F., Ye, R., Katz, S. R., Schultz, A. P., Johnson, K. A., Gómez‐Isla, T., Frosch, M. P., Growdon, J. H., & Gomperts, S. N. (2019) · Neurology · doi:10.1212/wnl.0000000000007855 · Cited by 33
From clinical phenotype to proteinopathy: molecular neuroimaging in neurodegenerative dementias
Studart‐Neto, A., & Coutinho, A. M. (2022) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x-anp-2022-s138 · Cited by 32
First-in-Rat Study of Human Alzheimer’s Disease Tau Propagation
Smolek, T., Jadhav, S., Brezováková, V., Cubinkova, V., Valachova, B., Novák, P., & Žilka, N. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1102-0 · Cited by 32
Sakr, F. A., Grothe, M. J., Cavedo, E., Jelistratova, I., Habert, M., Dyrba, M., González‐Escamilla, G., Bertin, H., Locatelli, M., Lehéricy, S., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0466-3 · Cited by 32
“signal and the currently used thresholds fail to recognize initial amyloid phases [2].”
BackgroundResultInfluentialPEG-Ceramide Nanomicelles Induce Autophagy and Degrade Tau Proteins in N2a Cells
Gao, J., Chen, X., Ma, T., He, B., Li, P., Zhao, Y., Ma, Y., Zhuang, J., & Yin, Y. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s258311 · Cited by 31
Reddy, J. S., Allen, M., Ho, C. C. G., Oatman, S. R., İş, Ö., Quicksall, Z., Wang, X., Jin, J., Patel, T., Carnwath, T., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01199-2 · Cited by 32
Self-citationKováčech, B., Cullen, N. C., Novák, P., Hanes, J., Kontseková, E., Katina, S., Parrák, V., Fresser, M., Vanbrabant, J., Feldman, H., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01620-7 · Cited by 30
Joint associations of β-amyloidosis and cortical thickness with cognition
Knopman, D. S., Lundt, E. S., Therneau, T. M., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., Machulda, M. M., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.01.017 · Cited by 30
“This meta-ROI was based on our prior work (Jack et al., 2008), and has been validated neuropathologically (Murray et al., 2015).”
MethodSelf-citationNeuropathologic basis of frontotemporal dementia in progressive supranuclear palsy
Sakae, N., Josephs, K. A., Litvan, I., Murray, M. E., Duara, R., Uitti, R. J., Wszołek, Z. K., Graff‐Radford, N. R., & Dickson, D. W. (2019) · Movement Disorders · doi:10.1002/mds.27816 · Cited by 30
Self-citationDerby, C. A. (2020) · Current Epidemiology Reports · doi:10.1007/s40471-020-00231-8 · Cited by 30
Alami, M., Boumezough, K., Zerif, E., Zoubdane, N., Khalil, A., Bunt, T., Laurent, B., Witkowski, J. M., Ramassamy, C., Boulbaroud, S., et al. (2024) · Nutrients · doi:10.3390/nu16213667 · Cited by 30
Knopman, D. S., Jack, C. R., Lundt, E. S., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.06.003 · Cited by 26
Self-citationOatman, S. R., Reddy, J. S., Quicksall, Z., Carrasquillo, M. M., Wang, X., Liu, C., Yamazaki, Y., Nguyen, T., Malphrus, K. G., Heckman, M. G., et al. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00592-2 · Cited by 29
Self-citationTeipel, S. J., Bakardjian, H., González‐Escamilla, G., Cavedo, E., Weschke, S., Dyrba, M., Grothe, M. J., Potier, M., Habert, M., Dubois, B., et al. (2017) · NeuroImage Clinical · doi:10.1016/j.nicl.2017.10.031 · Cited by 29
“In fact, according to neuropathological studies the great majority of individuals in the considered age range of our study show at least neocortical amyloid load of Thal phase 1, even when cognitively unimpaired at last clinical evaluation (Murray et al., 2015).”
BackgroundRappaport, A. N., Jacob, E., Sharma, V. K., Inberg, S., Elkobi, A., Ounallah-Saad, H., Pasmanik‐Chor, M., Edry, E., & Rosenblum, K. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.1170-15.2015 · Cited by 29
“There are numerous factors implicated as being involved in AD, such as TAU pathology, A 42 levels, plaque load, age, and the number of APOE 4 alleles (Murray et al., 2015).”
BackgroundRichardson, T. E., Walker, J. M., Farrell, K. W., Oliveira, T. G., White, C. L., & Crary, J. F. (2025) · Acta Neuropathologica · doi:10.1007/s00401-025-02943-x · Cited by 28
The Progressive Supranuclear Palsy: Past and Present Aspects
Parthimos, T. P., & Schulpis, K. H. (2019) · Clinical Gerontologist · doi:10.1080/07317115.2019.1694115 · Cited by 28
“(Bennett, Schneider, Wilson, Bienias, & Arnold, 2004; Duyckaerts et al., 1997; Murray et al., 2015; Sabbagh et al., 2010) MAPT has 2 haplotypes, H1 and H2.”
Valentino, R. R., Koga, S., Walton, R. L., Soto‐Beasley, A. I., Kouri, N., Deture, M. A., Murray, M. E., Johnson, P. W., Petersen, R. C., Boeve, B. F., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01097-z · Cited by 28
“Braak NFT stage [3] and Thal amyloid phase [22] were assessed for each CBD case based on the density and distribution of plaques and tangles as previously described [16].”
MethodSelf-citationYu, B., Shan, Y., & Ding, J. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-825 · Cited by 28
“Several studies have confirmed that these biomarkers can indeed be used to reliably measure disease-related brain changes in vivo (27,28).”
BackgroundManipulation of the diet–microbiota–brain axis in Alzheimer’s disease
Lee, D. D., Lee, V. M. ‐., & Hur, S. K. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.1042865 · Cited by 29
Insights into the pathological basis of dementia from population‐based neuropathology studies
Wharton, S. B., Simpson, J. E., Ince, P. G., Richardson, C. D., Merrick, R. L., Matthews, F. E., Brayne, C., & CFAS (2023) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12923 · Cited by 28
“This is consistent with other studies showing that NFT accumulation is highly associated with cognitive decline, and more so than amyloid.(35) All individuals with severe neocortical NFTs had dementia so that this was a perfect predictor with an infinite odds ratio.”
ResultHovakimyan, A., Antonyan, T., Shabestari, S. K., Svystun, O., Chailyan, G., Coburn, M., Carlen-Jones, W., Petrushina, I., Chadarevian, J. P., Zagorski, K., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-51809-2 · Cited by 28
Chen, C. D., Joseph‐Mathurin, N., Sinha, N., Zhou, A., Li, Y., Friedrichsen, K. A., McCullough, A. A., Franklin, E. E., Hornbeck, R. C., Gordon, B. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02342-y · Cited by 28
“4 was approximately equivalent to a Thal phase of 1–2, and that Thal phase, but not Braak NFT stage or cerebral amyloid angiopathy (CAA) score, predicted PiB PET summary region SUVRs [53].”
BackgroundSelf-citationImaging Biomarkers of Alzheimer Disease in Multiple Sclerosis
Zeydan, B., Lowe, V. J., Reichard, R. R., Przybelski, S. A., Lesnick, T. G., Schwarz, C. G., Senjem, M. L., Gunter, J. L., Parisi, J. E., Machulda, M. M., et al. (2020) · Annals of Neurology · doi:10.1002/ana.25684 · Cited by 27
“48).(38) Confirming our findings in an autopsy study with patients and controls drawn from the same cohort could resolve the inconsistency between the 2 studies.”
ResultSelf-citationGarbarino, S., & Lorenzi, M. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.117980 · Cited by 27
“This result is compatible with previous findings in histo–pathological and imaging studies of amyloid deposition in AD ( Braak and Braak, 1991; Fantoni et al., 2018; Grothe et al., 2017; Murray et al., 2015; Thal et al., 2018; 2002 ).”
Malpas, C. B., Sharmin, S., & Kalinčík, T. (2020) · International Journal of Neuroscience · doi:10.1080/00207454.2020.1758087 · Cited by 26
Assessment of Alzheimer-related pathologies of dementia using machine learning feature selection
Rajab, M. A., Jammeh, E., Taketa, T., Brayne, C., Matthews, F. E., Su, L., Ince, P. G., Wharton, S. B., Wang, D. Y. Q., & on behalf of the Cognitive Function and Ageing Neuropathology Study Group (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01195-9 · Cited by 25
The clinical importance of suspected non-Alzheimer disease pathophysiology
Vos, S. J. B., Delvenne, A., Jack, C. R., Thal, D. R., & Visser, P. J. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00962-y · Cited by 25
Self-citationPrediction of Cerebral Amyloid With Common Information Obtained From Memory Clinic Practice
Lee, J. H., Byun, M. S., Yi, D., Sohn, B. K., Jeon, S. Y., Lee, Y., Lee, J., Kim, Y. K., Lee, Y., & Lee, D. Y. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00309 · Cited by 25
“Each participant was classified as amyloid positive if the global SUVR value was >1.40 (Murray et al., 2015).”
BackgroundInfluentialLongitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes
Whitwell, J. L., Tosakulwong, N., Schwarz, C. C., Senjem, M. L., Spychalla, A. J., Duffy, J. R., Graff-Radford, J., Machulda, M. M., Boeve, B. F., Knopman, D. S., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010948 · Cited by 24
Self-citationThal, D. R., Ronisz, A., Tousseyn, T., Upadhaya, A. R., Balakrishnan, K., Vandenberghe, R. R., Vandenbulcke, M., Arnim, C. A. F. V., Otto, M., Beach, T. G., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01005-5 · Cited by 25
Nanobiotechnology in Neurodegenerative Diseases
Jampílek, J., Kráľová, K., Novák, P., & Novák, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_4 · Cited by 24
Morderer, D., Wren, M. C., Liu, F., Kouri, N., Maistrenko, A., Khalil, B., Pobitzer, N., Salemi, M., Phinney, B. S., Bu, G., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00817-0 · Cited by 23
Self-citationHessen, E., Nordlund, A., Stålhammar, J., Eckerström, M., Bjerke, M., Eckerström, C., Göthlin, M., Fladby, T., Reinvang, I., & Wallin, A. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150109 · Cited by 23
Future Directions in Imaging Neurodegeneration
Masdeu, J. C. (2017) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-017-0718-1 · Cited by 23
Fu, L., Li, Y., Hu, Y., Zheng, Y., Yu, B., Zhang, H., Wu, J., Wu, H., Yu, X., & Kong, W. (2017) · Scientific Reports · doi:10.1038/srep41041 · Cited by 22
Regional analysis and genetic association of nigrostriatal degeneration in Lewy body disease
Kasanuki, K., Heckman, M. G., Diehl, N. N., Murray, M. E., Koga, S., Soto, A. I., Ross, O. A., & Dickson, D. W. (2017) · Movement Disorders · doi:10.1002/mds.27184 · Cited by 22
Self-citationAβ and Tau Prions Causing Alzheimer’s Disease
Condello, C., Merz, G. E., Aoyagi, A., DeGrado, W. F., & Prusiner, S. B. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2655-9_16 · Cited by 21
Plowey, E. D., & Ziskin, J. L. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0388-2 · Cited by 21
Majd, S., Power, J. H. T., Koblar, S. A., & Grantham, H. J. M. (2016) · IBRO Reports · doi:10.1016/j.ibror.2016.12.002 · Cited by 21
PET Neuroimaging in Dementia Conditions
Perani, D., Caminiti, S. P., Carli, G., & Tondo, G. (2020) · Springer eBooks · doi:10.1007/978-3-030-53168-3_9 · Cited by 21
Plexin-A4 mediates amyloid-β–induced tau pathology in Alzheimer’s disease animal model
Chung, S., Yang, J., Kim, H. J., Hwang, E. M., Lee, W., Suh, K. Y., Choi, H., & Mook‐Jung, I. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2021.102075 · Cited by 20
Moffat, G. L., Zhukovsky, P., Coughlan, G., & Voineskos, A. N. (2022) · Brain Communications · doi:10.1093/braincomms/fcac282 · Cited by 20
Engels, N., Riphagen, J. M., Egroo, M. V., Koops, E. A., Smegal, L. F., Becker, J. A., Prokopiou, P. C., Bueichekú, E., Kwong, K. K., Rentz, D. M., et al. (2024) · Annals of Neurology · doi:10.1002/ana.27022 · Cited by 20
Goyal, M. S., Gordon, B. A., Couture, L. E., Flores, S. E., Xiong, C., Morris, J. C., Raichle, M. E., Benzinger, T. L. S., & Vlassenko, A. G. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.08.019 · Cited by 20
Metadata
- Authors
- Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., Ross, O. A., Duara, R., Knopman, D. S., Jack, C. R., & Dickson, D. W.
- Affiliations
- Mayo Clinic (US)
- University of Miami (US)
- Corresponding author
- Murray, Melissa E.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-03-23
- Volume
- 138
- Issue
- 5
- Pages
- 1370-1381
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC4407190
- OpenAlex
- W2148457471
- Cited by
- 324
- References
- 72
- Citations by year
- 2026: 9 · 2025: 18 · 2024: 22 · 2023: 15 · 2022: 18 · 2021: 32 · 2020: 38 · 2019: 41 · 2018: 34 · 2017: 36 · 2016: 35 · 2015: 25
- FWCI
- 35.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Alzheimer's Association
- National Institute on Aging (R01AG040042, U01AG006786, R01AG011378, R01AG041851, P50AG016574)
- National Institute of Neurological Disorders and Stroke (P50NS072187)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, 11C-Pittsburgh compound B, amyloid PET, amyloid plaques, APOE ε4, cerebral amyloid angiopathy, thioflavin S staining, age of onset, disease duration, amyloid biomarkers
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Amyloid, Aniline Compounds, Female, Humans, Male, Middle Aged, Thiazoles, Amyloid beta-Peptides, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.